Givinostat (Duvyzat): First Non-Steroidal DMD Treatment

Givinostat, marketed as Duvyzat, is the first non-steroidal treatment approved by the United States Food and Drug Administration for Duchenne muscular dystrophy. It is also the first FDA-approved DMD therapy that applies across all DMD genetic variants, not only those eligible for mutation-specific approaches.

What givinostat is

Givinostat is an oral histone deacetylase, or HDAC, inhibitor. HDACs are enzymes that influence how DNA is packaged and how genes are expressed.

In DMD, the absence of functional dystrophin sets off a cascade of muscle damage, inflammation, and fibrosis. Givinostat appears to act on several steps in that cascade by inhibiting HDAC overactivity, with downstream effects on inflammation, fibrosis, and muscle regeneration. (Duvyzat product information via PMC)

It is not a cure. It is intended to slow the rate of disease progression.

The approval

On March 21, 2024, the FDA approved Duvyzat for the treatment of Duchenne muscular dystrophy in patients ages 6 and older. The approval was based primarily on the EPIDYS Phase 3 trial. (FDA, nonsteroidal treatment for Duchenne)

EPIDYS was a randomized, double-blind, placebo-controlled study. It met its primary endpoint by showing a better outcome on a four-stair climb assessment from baseline to 72 weeks in the givinostat group compared to placebo. Results were published in The Lancet Neurology.

The European Medicines Agency has recommended givinostat for conditional marketing authorisation in the European Union for ambulatory patients ages 6 and older.

Who it is for

The current US label covers patients with DMD ages 6 and older. Unlike exon-skipping therapies, which are mutation-specific, givinostat is not restricted to a particular DMD mutation.

In practice, eligibility also depends on age, mobility status, organ function, concurrent medications, and the prescribing clinician’s judgment. As with any approved DMD therapy, eligibility for use is not the same as eligibility for funded access.

How it is used

Givinostat is taken orally. It is typically prescribed alongside corticosteroids, not as a replacement for them, although the relationship between glucocorticoid choice and HDAC inhibition continues to be studied.

Common adverse events in the clinical program included diarrhea, abdominal pain, thrombocytopenia, and elevations in triglycerides. Monitoring of blood counts and lipid levels is part of routine follow-up.

Why “non-steroidal” matters

Corticosteroids remain a cornerstone of DMD care. They have meaningful benefits and significant side effects, including weight gain, growth suppression, behavior changes, bone fragility, and adrenal suppression.

A non-steroidal mechanism does not replace the need for steroids in most patients. It adds a different lever. The longer-term question is how non-steroidal and steroid-modifying therapies will be combined in standard care.

For background, see corticosteroids in DMD and vamorolone explained.

Cost and access

Givinostat is priced as a specialty therapy. Coverage varies by payer and country. Access outside the United States depends on local approval, reimbursement, and prescribing infrastructure.

For background, see DMD treatment cost and DMD treatment access by country.

What is still uncertain

Open questions include long-term durability of effect, optimal patient selection, combination strategies with other approved DMD therapies, and real-world adherence. The post-marketing period will generate evidence on each.

The reasonable framing is that givinostat is a new class of DMD therapy with meaningful trial data and ongoing learning. The decisions belong to the care team.

For related reading, see the reported piece Duchenne, drug approval, and public policy.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.